Skye Bioscience Inc (FRA:09R)

Q1 2025 Skye Bioscience Inc Earnings Call Transcript

May 8, 2025 / 08:30 PM GMT

Release Date Price: €1.41 (-2.08%)

Transcript 8-K10-Q

Key Points

Positve

Skye Bioscience Inc (SKYE) completed enrollment in their phase 2A CB1 trial ahead of schedule, allowing for an extension to 52 weeks to collect longer-term data.
The company generated compelling new preclinical data validating the potential of nemasimab as a weight loss therapy, showing significant weight loss and glycemic control.
Recent studies demonstrated that nemasimab can provide additive weight loss when combined with incretin mimetics like tirzepatide.
The data safety monitoring committee completed three reviews with no safety concerns, indicating a strong safety profile for their ongoing trials.
Skye Bioscience Inc (SKYE) has a solid financial position with cash and investments totaling $59.2 million, expected to fund operations through Q1 2027.

Negative

The company faces regulatory uncertainty due to potential shifts in drug pricing policy and changes at the FDA and NIH.
Research and development expenses increased significantly to $7.2 million from $1.9 million year-over-year, impacting financials.
General administrative expenses also rose, primarily due to increased investor relations, marketing, and consulting costs.
The net loss for the quarter was $11.1 million, more than double the loss from the same period in 2024.
There is ongoing concern about the evolving policy environment and its potential impact on drug pricing and regulatory oversight.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SKYE.OQ - Skye Bioscience Inc
Q1 2025 Skye Bioscience Inc Earnings Call
May 08, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello, and thank you all for participating in today's call. Joining me today is Pannet Dillon, Sky's President and CEO Chris Twitty, CSO, and Caitlin Arsenal, Sky's CFO.

Before we begin, I'd like to caution that comments made during this conference call will contain forward-looking statements under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1,995, including statements about Sky's expectations regarding its development activities, timelines, and milestones.

Forward-looking statements are subject to risk and uncertainties that could cause actual results to differ materially and adversely, and reported results should not be considered as an indication of future performance.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.